MKMichael H. Kinzer

Michael H. Kinzer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michael H. Kinzer has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A Review of Malaria, Diphtheria, and Botulism Medication Distributions by CDC Port Health Stations From May 2006 to February 2024

    by Lily Rubin, Jennifer Fowler, Srikar Ranga, Máire Kirley, Joshua Tchan, Maria Pacheco, Leigh Ellyn Preston, Michelle A. Waltenburg, Olubunmi Akinkugbe, Michael H. Kinzer, et al.

    Objectives: The Centers for Disease Control and Prevention (CDC) maintains a formulary of biologic agents and drugs not available commercially in the United States. For a subset of these (botulism and diphtheria antitoxins and, until 2022, intravenous artesunate for severe malaria), distribution is coordinated through CDC port health stations (PHS), located mainly at major US international airports. CDC aims for these drugs to reach their destinations within 8 hours of release authorization. We analyzed CDC records to identify areas for efficiency improvement. Design: We queried records detailing drug distributions from PHS that occurred May 2006 to February 2024, including timing of release authorization and delivery, geographic origins and destinations, mode of transportation, and patient characteristics and outcomes. We conducted descriptive and multivariate analyses to identify variables that may have delayed delivery. Setting: CDC port health stations. Main Outcome Measures: Time from release authorization to drug delivery. Results: CDC PHS distributed 2912 drug shipments between May 2006 and February 2024 via 17 distribution sites to 54 jurisdictions across the US and 3 countries. Of 850 shipments for which data were available (those occurring December 2019 or later), 83% (n = 702/850) occurred within 8 hours of authorization. Commercial air transport (compared to other types of transport) (aOR: 11.43, 95% confidence interval [CI]: 6.94-18.81, P < .001) and release authorization time (outside of vs within routine work hours) (aOR: 5.10, 95% CI: 3.31-7.86, P < .001) were significantly associated with delays. Conclusions: CDC PHS facilitated emergency distributions of life-saving drugs for botulism, diphtheria, and severe malaria to locations throughout the US mostly within 8 hours of authorization. Staffing, distribution locations, and expanded options for ground transportation are important considerations that may minimize delays.

  • A Review of Reports to CDC of Travelers Who Flew While Infectious With Pertussis From April 2013 to February 2024

    by Kristen Pringle, Robert Mason Clark, Jennifer J Fowler, Shannon L Gearhart, Leslie Hausman, Paisley Rearden, Grayson K Walker, Michael Kinzer, Leigh Ellyn Preston, Clive Brown, et al.

    Context: Pertussis is endemic worldwide, and exposure can occur anywhere, including commercial aircraft. Travelers exposed to an infectious person with pertussis may receive post-exposure prophylaxis (PEP) for up to 21 days after exposure to decrease risk of infection. This is accomplished through the identification of infectious travelers and their aircraft contacts (a process called aircraft contact investigation [Air CIs]). Objective: Describe travelers reported to the US Centers for Disease Control and Prevention (CDC) who flew while infectious with pertussis and outcomes of associated Air CIs. Design: CDC’s Port Health Activity Reporting System (PHARS) was queried to identify reports of travelers who flew with pertussis from April 12, 2013, to February 28, 2024. Participants: Index cases (passengers or crew members) with pertussis who traveled on commercial aircraft and their exposed passenger contacts. Main Outcome Measure(s): Traveler demographics, flight characteristics, outcome data from Air CIs. Results: Three hundred and eight individuals who recently traveled on commercial aircraft with pertussis were identified. Of the passengers determined to be infectious on the flights, Air CIs were initiated for 102/270 (38%) travelers who flew on 163/500 (33%) flights. Among the 337/500 (67%) flights for which Air CI was not initiated, the most common reason was that the index case was seated adjacent to only household members (142/337, 42%). For flights in which Air CIs were initiated, 234 contacts were identified, and one secondary case in a non-household passenger contact was reported. The average time from when contacts were exposed during the flight to when a health department reported the index case to CDC was 11.6 days (median 10.3 days, range: 0-39 days). Conclusions: Timely reporting of pertussis cases after air travel may decrease transmission risk to passenger contacts and prevent severe illness.


  • Open Access

    A survey of knowledge, attitudes, and practices towards skin and soft tissue infections in rural Alaska

    by Gregory A. Raczniak, Joanna Gaines, Lisa R. Bulkow, Michael H. Kinzer, Thomas W. Hennessy, Joseph A. Klejka, Michael G. Bruce

    A survey of knowledge, attitudes, and practices towards skin and soft tissue infections in rural Alaska